



**SANDHILLS
CENTER**



Cervical cancer and human papillomavirus screening

Clinical Policy ID: CCP.1280

Recent review date: 11/2021

Next review date: 3/2023

Policy contains: Cervical cancer; cytology (Papanicolaou test); high-risk human papillomavirus test.

This policy is a Sandhills Center Clinical Coverage Policy adopted from AmeriHealth Caritas of North Carolina. These clinical policies are used to assist with making coverage determinations. Sandhills Center's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by Sandhills Center when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Sandhills Center clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Sandhills Center's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Sandhills Center will update its clinical policies as necessary. Sandhills Center clinical policies are not guarantees of payment.

Coverage policy

Screening for cervical cancer and human papillomavirus using clinician-collected samples is clinically proven and, therefore, medically necessary when all of the following criteria are met (National institute of health, 2019; American College of Obstetricians and Gynecologists, 2019; U.S. Preventive Services Task Force, 2018):

- All female members ages 21 to 65 years with a cervix without signs or symptoms of cervical cancer, regardless of their sexual history or human papillomavirus vaccination status, and not at high risk¹ for cervical cancer.
- Screening intervals:
 - Age 21 to 29 years — Pap cytology alone every three years.
 - Age 30 to 65 years — Pap cytology every three years for high-risk human papillomavirus co-testing every five years, high-risk human papillomavirus testing every five years, or Pap cytology alone every three years.

¹ Factors associated with increased risk of cervical cancer include a compromised immune system, in utero exposure to
CCP.1280

diethylstilbestrol, and previous treatment of a high-grade precancerous lesion or cervical cancer.

- Routine screening should continue for at least 20 years after spontaneous regression or appropriate management of a high-grade precancerous lesion, even if this extends screening past age 65 years.
 - Age > 65 years who have not been adequately screened or are otherwise at high risk.
 - End of screening criteria:
 - Age > 65 years assuming three consecutive negative results on cytology or two consecutive negative results on co-testing within 10 years before cessation of screening, with the most recent test performed within five years.
 - Total hysterectomy (specifically for members without a cervix and without a history of cervical intra-epithelial neoplasia 2, cervical intra-epithelial neoplasia 3, adenocarcinoma *in situ*, or cancer in the past 20 years).
 - Once screening has stopped, it should not resume in women ages 65 years or older, even if they report having a new sexual partner.
 - Members at high risk for cervical cancer should receive individualized follow-up.

For Medicare members only

Medicare covers a screening pelvic examination and Papanicolaou test for all female beneficiaries at 12- or 24-month intervals, based on specific risk factors. See 42 C.F.R. § 410.56; Medicare National Coverage Determinations Manual, § 210.2.1. Current Medicare coverage does not include the human papillomavirus testing. Pursuant to §1861(ddd) of the Social Security Act, the Secretary may add coverage of "additional preventive services" if certain statutory requirements are met.

Effective for services performed on or after July 9, 2015, human papillomavirus testing can be added once every five years as an additional preventive service benefit under the Medicare program for asymptomatic beneficiaries ages 30 to 65 years in conjunction with the Papanicolaou smear test. The Centers for Medicare & Medicaid Services will cover screening for cervical cancer with the appropriate U.S. Food and Drug Administration-approved/cleared laboratory tests, used consistent with U.S. Food and Drug Administration-approved labeling and in compliance with the Clinical Laboratory Improvement Act regulations (National Coverage Determination 210.2.1).

Limitations

All other screening tests for cervical cancer and human papillomavirus are not medically necessary, including high risk human papillomavirus testing using vaginal deoxyribonucleic acid or Papanicolaou liquid-based cytology using self-sampling devices (American College of Obstetricians and Gynecologists, 2019; Arbyn, 2018).

Cervical cancer screening is not medically necessary for members (American College of Obstetricians and Gynecologists, 2017, 2019; U.S. Preventive Services Task Force, 2018):

- Younger than 21 years.
- Older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer.
- Who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion or cervical cancer.

There is no role for testing for low-risk genotypes, and tests for low-risk human papillomavirus should not be performed (American College of Obstetricians and Gynecologists, 2019; U.S. Preventive Services Task Force, 2018).

Alternative covered services

Human papillomavirus vaccination in accordance with the recommendations of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices listed in the appendix.

Background

Cervical cancer is one of the most common malignancies in women and remains a significant cause of morbidity and mortality worldwide. Despite decreasing mortality rates for all U.S. women, significant racial disparities in the risk of death from cervical cancer persist (Collins, 2013; Mann, 2015).

Human papillomavirus infection is the most significant risk factor for pre-invasive cervical lesions and cervical cancer, as human papillomavirus infection of epithelial cells can induce malignant growth in humans (American Cancer Society, 2020). Most human papillomavirus infections resolve spontaneously, but persistent high-risk human papillomavirus infection can lead to precancerous cervical intra-epithelial neoplasia, which can become invasive. The majority of cervical carcinomas are squamous cell; the remainder are adenocarcinomas, adenosquamous carcinomas, and cancers of undifferentiated cell types. However, human papillomavirus is found in many women who never develop the disease.

Screening for cervical cancer

Identification and treatment of cervical lesions through screening reduces cervical cancer incidence, morbidity, and mortality. Detection of early-stage asymptomatic cancer also contributes to decreased morbidity by making women eligible for treatments with lower morbidity (Peirson, 2013). Cervical cytology with liquid-based, thin layer preparation, *in situ* hybridization, polymerase chain reaction, and hybrid capture technology are available to test for human papillomavirus strains.

The U.S. Food and Drug Administration (2020) has approved several human papillomavirus deoxyribonucleic acid and ribonucleic acid tests as adjuncts to cytology screening for women ages 30 and older, including one (Cobas® HPV Test, Roche Molecular Systems Inc., Pleasanton, California) that received specific approval as a primary screening test for women ages 25 years and older to detect high-risk human papillomavirus types 16 and 18 — the two types that cause 70% of cervical cancers. In 2018, the BD Onclarity HPV Assay (Becton, Dickinson, and Company, Sparks, Maryland) received regulatory approval as a primary screening test in women age 25 years and older. Other potential uses for human papillomavirus deoxyribonucleic testing include triage of patients with atypical squamous cells of undetermined significance, follow-up after treatment, follow-up for patients with abnormal cytology, and resolution of discrepancies in colposcopy or histology findings.

Human papillomavirus vaccination

The U.S. Food and Drug Administration has approved a bivalent, quadravalent, and most recently, a 9-valent recombinant human papillomavirus vaccine for protection against some of the more common human papillomavirus infections (U.S. Food and Drug Administration, 2018a). Immunizing women and men prior to infection can reduce the risk for cervical cancer, although the effectiveness and duration of the vaccine continues to be evaluated.

The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices issued new recommendations for a two-dose schedule for human papillomavirus vaccination (Gardasil) of girls and boys who initiate it at ages nine through 14 years of age (Meites, 2016). The change was based on available immunogenicity evidence that showed equivalent efficacy of a two-dose schedule (zero, six to 12 months) to a three-dose schedule (zero, one to two, six months) if the human papillomavirus vaccination series is initiated before the 15th birthday. At its June 2019 meeting, the Committee updated recommendations for catch-up vaccination for all individuals through age 26 who are not adequately vaccinated and based on shared clinical

decision making also for individuals aged 27 through 45 years who are not adequately vaccinated (Meites, 2019). Human papillomavirus vaccines are not licensed for use in adults older than age 45 years. Dosing schedules, intervals, and definitions of persons considered adequately vaccinated have not changed. The updated recommendations are detailed in the appendix.

Findings

Both conventional and liquid-based techniques for Papanicolaou tests are acceptable for screening. Conventional cytology is less costly than the liquid-based; however, the liquid-based technique is able to screen for human papillomavirus and other infections. The evidence suggests a role for human papillomavirus-cytology co-testing as an initial screening strategy in average-risk women ages 30 to 65 years, but the evidence for use of human papillomavirus alone as an initial testing strategy or as triage for abnormal cytology results is inconclusive (Bouchard-Fortier, 2014).

The potential harms associated with cervical screening with cytology or human papillomavirus testing are both physical and emotional (Vesco, 2011). Abnormal test results can lead to more frequent testing and invasive diagnostic procedures, such as colposcopy and cervical biopsy, and increased anxiety and distress. False-negative Papanicolaou test results may occur as a result of many factors such as slide preparation, laboratory, and reporting inaccuracies. The potential for over-diagnosis in the absence of benefit can lead to unnecessary surveillance, diagnostic tests, and treatments with associated harms.

Recent evidence-based guidelines for screening have refined the approach to minimize harms and maximize benefits. In general, the approach has focused on increasing the age at which to begin screening, lengthening the screening interval, incorporating human papillomavirus testing, and discontinuing screening in women at low risk for future cervical cancer. In 2012, the U.S. Preventive Services Task Force, American College of Obstetricians and Gynecologists, and American Cancer Society, in collaboration with the American Society for Colposcopy and Cervical Pathology and the American Society for Clinical Pathology, released revised recommendations for cervical cancer screening (Saslow, 2012). Guidelines by the American Academy of Family Physicians (2020) follow U.S. Preventive Services Task Force recommendations. For the first time, these guidelines agreed on the populations to whom the recommendations apply, the ages at which to begin and end screening, the appropriate screening intervals, and the appropriate tests to be used.

The effect of human papillomavirus vaccination on the need for screening with cytology alone or in combination with human papillomavirus testing is not established. Given these uncertainties, women who have been vaccinated should continue to be screened (U.S. Preventive Services Task Force, 2016). The following recommendations apply to women of average risk with a cervix, regardless of human papillomavirus vaccination status and sexual history. These recommendations do not apply to women who have received a diagnosis of a high-grade precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, or women who are immunocompromised (e.g., human immunodeficiency virus positive):

- Begin screening with cytology at the age of 21, regardless of the onset of sexual activity, and continue every three years until the age of 29.
- From ages 30 to 65, human papillomavirus-cytology co-testing every five years is preferred; cytology alone every three years is also acceptable.

Although recommendations have resulted in reductions in screening post-hysterectomy and of those ages ≥ 65 years, many women still are being screened who will not benefit from it (Centers for Disease Control and Prevention, 2013). Specific recommendations for these women are as follows:

- For women ages > 65 years, no screening is recommended following adequate negative prior screening.

Adequate prior screening is defined as three consecutive negative cytology results or two consecutive

negative human papillomavirus results within 10 years before cessation of screening, with the most recent test occurring within five years. Women with a history of cervical intra-epithelial neoplasia 2 or a more severe diagnosis should continue routine screening for at least 20 years after spontaneous regression or appropriate management of a high-grade precancerous lesion, even if this extends screening past age 65 years. Screening should not resume after cessation in women older than age 65 years, even if a woman reports having a new sexual partner.

- No screening is recommended for women without a cervix, without a history of cervical intra-epithelial neoplasia 2 or a more severe diagnosis in the past 20 years, or cervical cancer ever.

Abnormal results are interpreted commonly using two systems. The Cervical intraepithelial neoplasia system (CIN 1-CIN3) and the Bethesda system. The Bethesda System terminology is as follows:

- ASC-US (Atypical Squamous Cells of Undetermined Significance): Means the results look borderline between “normal” and “abnormal” – often not HPV-related
- ASC-H (Atypical Squamous Cells-cannot exclude HSIL): Borderline results, but may really include High-Grade lesions.
- Low-Grade SIL (LSIL) and High-Grade SIL (HSIL): SIL stands for squamous intraepithelial lesion. LSILs are considered mild abnormalities usually caused by an HPV infection. HSILs are considered more severe abnormalities and have a greater chance of progressing to invasive cancer. Treatment is based on these results. Women with abnormal Papanicolaou test results are usually followed more closely for cervical problems which may involve coming back for a colposcopy and biopsy, or having a repeat Papanicolaou test in a few months. If the Papanicolaou result is “ASC-US,” then a HPV-DNA test may be done in the lab to see whether HPV is causing this borderline “normal-abnormal” Papanicolaou result (National cervical cancer coalition, 2021). If there is confirmation a colposcopy, cervical biopsy, cone biopsy and a Loop electro-surgical excision procedure (LEEP) may be performed to eradicate the precancerous cells and closer follow up would resume (National cervical cancer coalition, 2021).

A new Cochrane review of randomized controlled trials found primary high-risk human papillomavirus screening is at least as effective as cytology alone at the same screening intervals (Koliopoulos, 2017). Human papillomavirus tests are less likely to miss cases of cervical intra-epithelial neoplasia 2+ and cervical intra-epithelial neoplasia 3+, but may lead to more false positives and unnecessary referrals. On the other hand, cytology has a greater chance of being falsely negative, which could delay appropriate treatment.

The U.S. Preventive Services Task Force (2016) now recommends primary high-risk human papillomavirus testing in their draft screening algorithm for average-risk women ages 30 to 65 years as an alternative to cytology screening alone; co-testing is no longer recommended in this age group. The American College of Obstetricians and Gynecologists (2016) continues to recommend cytology alone every three years or co-testing at five-year intervals. The recommendations of both organizations for routine cervical cancer screening in women younger than 21 years, for women ages 21 to 29 years, and for women older than 65 years who have been adequately screened previously have not changed.

In 2018, the U.S. Preventive Services Task Force finalized recommendations for cervical cancer screening to include three screening strategies for average-risk women ages 30 to 65 years: high-risk human papillomavirus testing alone every five years; cervical cytology alone every three years or cytology; and high-risk human papillomavirus co-testing testing every five years. All three screening strategies offer a reasonable balance between benefits and harms in this cohort. The American College of Obstetricians and Gynecologists (2018) is reviewing these new recommendations and, in the interim, affirms its current cervical cancer screening guidelines that encompass all three cervical cancer screening options for women at average risk of cervical cancer. The recommendations of both organizations for the other age groups has not changed. The policy was

changed to include high-risk human papillomavirus testing alone every five years as a screening strategy in this cohort of women. The policy ID was changed from CP# 13.01.03 to CCP.1280.

In 2019, we added new research on the clinical validity and utility of samples collected by the patient (self samples) as a means of increasing cervical cancer screening compliance for under-screened women. Theoretically, self sampling with high risk human papillomavirus testing using vaginal deoxyribonucleic acid or with liquid-based cervical cytology may remove the need for a clinician to perform initial screening, thereby allowing clinical services to be organized around follow-up. However, the evidence of effectiveness or cost effectiveness (utility) is insufficient to support self sampling for either test in cervical cancer screening.

The research on self-sampled liquid-based cytology is in its preliminary stages. In January 2018(b), a U.S. Food and Drug Administration workshop explored the feasibility of evaluating cervical self-sample devices used for cervical cancer screening by Papanicolaou testing. In contrast, self sampling using high-risk human papillomavirus assays has been assessed in multiple studies. A meta-analysis (Arbyn, 2018) of 56 accuracy studies and 25 participation trials found that, compared to clinician samples, self samples using high-risk human papillomavirus assays based on polymerase chain reaction showed comparable sensitivity for detecting cervical intra-epithelial neoplasia 2+ or cervical intra-epithelial neoplasia 3+ (pooled ratio 0.99, 95% confidence interval 0.97 to 1.02), whereas those assays based on signal amplification were less sensitive (pooled ratio 0.85, 95% confidence interval 0.80 to 0.89). The specificity of self samples to exclude cervical intra-epithelial neoplasia 2+ with high-risk human papillomavirus assays based on either polymerase chain reaction or signal amplification was 2% and 4% lower than that of clinician samples, respectively.

The American College of Obstetricians and Gynecologists (2017) recommends human papillomavirus testing as an acceptable alternative cervical cancer screening methodology in low-resource settings where cytology-based screening is not feasible or practical, e.g., in the U.S. Affiliated Pacific Islands. The optimal screening strategy incorporating self samples requires further study, particularly in areas with more organized screening programs (American College of Obstetricians and Gynecologists, 2017; U.S. Preventive Services Task Force, 2018). We added a statement about self samples to the limitations section and clarified that samples be collected by the clinician in the coverage section.

In 2020 and 2021, we updated American College of Obstetricians and Gynecologists guidance on human papillomavirus vaccination (2020, update of 2017). We added four systematic reviews (Biddell, 2020; Caleia, 2020; Connolly, 2020; Malone, 2020) that provide limited evidence suggesting a patient preference for human papillomavirus self sampling over traditional Papanicolaou screening, which may overcome some of the barriers to screening, particularly among medically underserved populations. However, the evidence of clinical utility and cost-effectiveness is insufficient to support widespread use of human papillomavirus self sampling as a screening test. No policy changes are warranted.

References

On August 13, 2021, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “cervical intraepithelial neoplasia” (MeSH), “uterine cervical dysplasia” (MeSH), “early detection of cancer” (MeSH), “human papillomavirus screening,” “cervical cancer screening” and “human papillomavirus vaccines” (MeSH). We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

American Academy of Family Physicians. Clinical preventive service recommendation. Cervical cancer. <http://www.aafp.org/patient-care/clinical-recommendations/all/cervical-cancer.html>. Accessed August 16, 2021.

American Cancer Society. What are the risk factors for cervical cancer?

<https://www.cancer.org/cancer/cervical-cancer/prevention-and-early-detection/cervical-cancer-risk-factors.html>.

Last updated January 3, 2020. Accessed August 16, 2021.

American College of Obstetricians and Gynecologists. Committee on Adolescent Health Care and Immunization Expert Work Group. Committee opinion 809 human papillomavirus vaccination

<https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/08/human-papillomavirus-vaccination> . Published August 2020. Accessed August 16, 2021.

American College of Obstetricians and Gynecologists. Committee on Health Care for Underserved Women. Committee opinion 624. Cervical cancer screening in low-resource settings. [https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-](https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Cervical-Cancer-Screening-in-Low-Resource-Settings)

[Women/Cervical-Cancer-Screening-in-Low-Resource-Settings](https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Cervical-Cancer-Screening-in-Low-Resource-Settings). Published February 2015. Reaffirmed 2017.

Accessed August 16, 2021.

American College of Obstetricians and Gynecologists. Practice advisory: Cervical cancer screening (update).

<https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Cervical-Cancer-Screening-Update>. Published 2018. Reaffirmed November 8, 2019. Accessed August 16, 2021.

American College of Obstetricians and Gynecologists. Practice bulletin No. 168: Cervical cancer screening and prevention. *Obstet Gynecol*. 2016 Oct;128(4):e111-130. Reaffirmed 2018. Doi:

10.1097/AOG.0000000000001699.

Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: Updated meta-analyses. *Bmj*. 2018;363:k4823. Doi:

10.1136/bmj.k4823.

Biddell CB, O'Leary MC, Wheeler SB, Spees LP. Variation in cervical cancer screening preferences among medically underserved individuals in the United States: A systematic review. *Cancer Epidemiol Biomarkers Prev*. 2020;29(8):1535-1548. Doi: 10.1158/1055-9965.epi-20-0306.

Bouchard-Fortier G, Hajifathalian K, McKnight MD, Zacharias DG, Gonzalez-Gonzalez LA. Co-testing for detection of high-grade cervical intraepithelial neoplasia and cancer compared with cytology alone: A meta-analysis of randomized controlled trials. *J Public Health (Oxf)*. 2014;36(1):46-55. Doi: 10.1093/pubmed/ftd057.

Caleia AI, Pires C, Pereira JF, Pinto-Ribeiro F, Longatto-Filho A. Self-sampling as a plausible alternative to screen cervical cancer precursor lesions in a population with low adherence to screening: A systematic review. *Acta Cytol*. 2020;64(4):332-343. Doi: 10.1159/000505121.

Centers for Disease Control and Prevention. Cervical cancer screening among women by hysterectomy status and among women aged ≥ 65 years — United States, 2000 – 2010. *MMWR Morb Mortal Wkly Rep*.

2013;61:1043-1047. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6151a3.htm>. Accessed August 16, 2021.

Centers for Disease Control and Prevention. Use of 9-valent human papillomavirus (HPV) vaccine: Morbidity and Mortality Weekly Report (MMWR), updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*. March 27, 2015;64(11):300-304.

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm>. Accessed August 16, 2021.

Centers for Medicare & Medicaid Services. National Coverage Determination. 210.2.1 Screening for Cervical Cancer with Human Papillomavirus (HPV). [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx)

[database/search/advanced-search.aspx](https://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx). Accessed August 16, 2021.

Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. *Gynecol Oncol*. 2014;133(2):353-361. Doi: 10.1016/j.ygyno.2013.12.039.

Connolly D, Hughes X, Berner A. Barriers and facilitators to cervical cancer screening among transgender men and non-binary people with a cervix: A systematic narrative review. *Prev Med*. 2020;135:106071. Doi: 10.1016/j.ypmed.2020.106071.

Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. *Cochrane Database Syst Rev*. 2017;8:CD008587. Doi: 10.1002/14651858.CD008587.pub2.

Malone C, Barnabas RV, Buist DSM, Tiro JA, Winer RL. Cost-effectiveness studies of hpv self-sampling: A systematic review. *Prev Med*. 2020;132:105953. Doi: 10.1016/j.ypmed.2019.105953.

Mann L, Foley KL, Tanner AE, Sun CJ, Rhodes SD. Increasing cervical cancer screening among US Hispanics/Latinas: A qualitative systematic review. *J Cancer Educ*. 2015;30(2):374-387. Doi: 10.1007/s13187-014-0716-9.

Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep*. 2016;65(49):1405-1408. Doi: 10.15585/mmwr.mm6549a5.

Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep*. 2019;68(32):698-702. Doi: 10.15585/mmwr.mm6832a3.

National Cervical Cancer Coalition, American Sexual Health Association. Cervical Cancer Screening: Pap and HPV Tests. Copyright 2021. <https://www.nccc-online.org/hpvcervical-cancer/cervical-cancer-screening/>. Accessed August 17, 2021.

National institute of health: National cancer institute. *HPV and Pap testing*. <https://www.cancer.gov/types/cervical/pap-hpv-testing-fact-sheet>. Reviewed December 20, 2019. Accessed August 17, 2021.

Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: A systematic review and meta-analysis. *Syst Rev*. 2013;2:35. Doi: 10.1186/2046-4053-2-35.

Saslow D, Solomon D, Lawson HW, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin*. 2012;62:147-172. Doi: 10.3322/caac.21139.

Sawaya GF, Kulasingam S, Denberg TD, Qaseem A; Clinical Guidelines Committee of American College of Physicians. Cervical cancer screening in average-risk women: Best practice advice from the Clinical Guidelines Committee of the American College of Physicians. *Ann Intern Med*. 2015 Jun 16;162(12):851-859. Doi: 10.7326/m14-2426.

U. S. Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(7):674-686. Doi: 10.1001/jama.2018.10897.

U.S. Food and Drug Administration. Human papillomavirus vaccine. <http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm172678.htm>. Updated January 31,

U.S. Food and Drug Administration. FDA Premarket Approval (PMA) database searched using product codes MAQ and OYB. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>. Accessed August 16, 2021.

Vesco KK, Whitlock EP, Eder M, et al. Screening for cervical cancer: A systematic evidence review for the U.S. Preventive Services Task Force. Evidence synthesis no. 86. AHRQ publication no. 11-05156-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. *Gynecologic oncology*. 2015;136(2):189-197. Doi: 10.1016/j.ygyno.2014.11.076.

Policy updates

11/2016: initial review date and clinical policy effective date: 2/2017

08/2017: Policy references updated.

11/2018: Policy references updated. Changes to coverage and policy number.

11/2019: Policy references updated. Changes to coverage and limitations.

11/2020: Policy references updated.

11/2021: Policy references updated.

Appendix

Use of a 2- or 3-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices

Routine and catch-up vaccination age groups:

- Routine human papillomavirus vaccination for all adolescents starting at age 11 or 12 years, but can be started at age 9 years, and through age 18 years if not previously adequately vaccinated.
- Catch-up vaccination for all individuals through age 26 years who were not adequately vaccinated previously.
- Catch-up vaccination for individuals aged 27 through 45 years who are not adequately vaccinated based on shared clinical decision making.
- Human papillomavirus vaccines are not licensed for use in adults older than age 45 years.
- No pre-vaccination testing is recommended to establish the appropriateness of human papillomavirus vaccination.

Two- or 3-dose series depending on age at initial vaccination:

- Age 9 through 14 years at initial vaccination: 2-dose series at 0, 6 to 12 months (minimum interval: 5 months; repeat dose if administered too soon).
- Age 15 years or older at initial vaccination: 3-dose series at 0, 1 to 2 months, 6 months (minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon).

Special situations:

- Immunocompromising conditions, including human immunodeficiency virus infection: 3-dose series as above. This recommendation does not apply to children ages < 15 years with asplenia; asthma; chronic

granulomatous disease; chronic liver disease; chronic lung disease; chronic renal disease; central nervous system anatomic barrier defects (e.g., cochlear implant); complement deficiency; diabetes; heart disease; or sickle cell disease.

- History of sexual abuse or assault: Start at age 9 years.
- Pregnancy: Human papillomavirus vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination. Individuals who are breastfeeding or lactating can receive human papillomavirus vaccine.

Persons vaccinated previously are considered adequately vaccinated:

- If initially vaccinated with 9-valent, quadravalent, or bivalent before their 15th birthday, and received two doses of any human papillomavirus vaccine at the recommended dosing schedule (0, six to 12 months), or three doses of any human papillomavirus vaccine at the recommended dosing schedule (0, one to two, six months).
- If initially vaccinated with 9-valent, quadravalent, or bivalent on or after their 15th birthday, and received three doses of any human papillomavirus vaccine at the recommended dosing schedule.
- 9-valent may be used to continue or complete a vaccination series started with quadravalent or bivalent.
- For persons who have been adequately vaccinated with bivalent or quadravalent, there is no Advisory Committee on Immunization Practices recommendation regarding additional vaccination with 9-valent.
- If the vaccination schedule is interrupted, the series does not need to be restarted. The number of recommended doses is based on the age at the administration of the first dose.

Contraindications and precautions:

- Persons with a history of immediate hypersensitivity to any vaccine component.
- Quadravalent and 9-valent are contraindicated for persons with a history of immediate hypersensitivity to yeast.
- Bivalent should not be used in persons with anaphylactic latex allergy.
- Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by phone (800-822-7967) or online (<https://vaers.hhs.gov>).

Source: Meites (2016, 2019).